On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir-Reference-Cited by-同舟云学术

On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir

Published:2016-06-16 Issue:11 Volume:36 Page:1611-1618
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Kowdley Kris V.¹,Nelson David R.²,Lalezari Jacob P.³,Box Terry⁴,Gitlin Norman⁵,Poleynard Gary⁶,Rabinovitz Mordechai⁷,Ravendhran Natarajan⁸,Sheikh Aasim M.⁹,Siddique Asma¹⁰,Bhore Rafia¹¹,Noviello Stephanie¹¹,Rana Khurram¹²

Affiliation:

1. Swedish Medical Center; Seattle WA USA

2. University of Florida; Gainesville FL USA

3. Quest Clinical Research; San Francisco CA USA

4. Clinical Research Centers of America; LLC; Murray UT USA

5. Atlanta Gastroenterology Associates; Atlanta GA USA

6. Digestive Health Specialists; Winston-Salem NC USA

7. University of Pittsburgh; Pittsburgh PA USA

8. Digestive Disease Associates; Baltimore MD USA

9. Gastrointestinal Specialists of Georgia; Marietta GA USA

10. Virginia Mason Medical Center; Seattle WA USA

11. Bristol-Myers Squibb Research and Development; Princeton NJ USA

12. Bristol-Myers Squibb Research and Development; Wallingford CT USA

Funder

Bristol-Myers Squibb

AbbVie

Gilead Sciences

Intercept

Merck

Trio Health

Evidera

Galectin

Immuron

NGM Biopharma

Novartis

Tobira

Enanta

Verlyx

UpToDate, Inc

Janssen

Boehringer Ingelheim

Conatus

Idenix

Ikaria

Salix

Sundise

Achillion

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13165/fullpdf

Reference20 articles.

1. Treatment of hepatitis C virus genotype 3-infection;Pol;Liver Int,2014

2. The global health burden of hepatitis C virus infection;Negro;Liver Int,2011

3. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis;Nkontchou;J Viral Hepat,2011

4. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C;Bochud;J Hepatol,2009

5. Steatosis in chronic hepatitis C: why does it really matter?;Asselah;Gut,2006

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen in Chronic Hepatitis C: A Systematic Review and Meta-Analysis;2024-09-12

2. A randomized, placebo‐controlled, dose‐escalation phase I/II multicenter trial of low‐dose cidofovir for BK polyomavirus nephropathy;Transplant Infectious Disease;2024-09-03

3. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery;Expert Opinion on Drug Discovery;2024-07-30

4. Focal coagulative necrosis of the liver in a patient with sustained virologic response to anti-hepatitis C virus therapy;Radiology Case Reports;2024-04

5. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study;eLife;2023-01-09